Associate Professor, Internal Medicine, Wayne State University School of Medicine
Oncology
Dr. Ulka N. Vaishampayan, MD
|
|
Give Review
Ulka Vaishampayan works in the field of Oncology. She researched medicine at Wayne State University School of Medicine. Wayne State University School of Medicine has a rank of 63 in research and a 85 in primary care Doctor Ulka N. Vaishampayan, MD has written publications. She has 88 publications published with PubMed. The lastest publication is: 'Multifaceted and personalized therapy of advanced prostate cancer.' She is registered with Medicare.
Publications
- A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate Cancer (CRPC)-a ...
- Activity of enzalutamide in men with metastatic castration-resistant prostate Cancer is affected by prior treatment with abiraterone and/or docetaxel.
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
- Prostate Cancer: Clinical implications of therapeutic sequence in mCRPC.
- The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma.
- Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Co...
- A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial Carcinoma.
- Therapeutic options and multifaceted treatment paradigms in metastatic castrate-resistant prostate Cancer.
- Sequencing therapy in advanced prostate Cancer: focus on sipuleucel-T.
- The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer...
- Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma.
- The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell Carcinoma p...
- Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy.
- Intermittent versus continuous androgen deprivation in prostate Cancer.
- Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective Analysis of pooled, prospec...
- Monoclonal antibodies in oncology therapeutics: present and future indications.
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial.
- Cabozantinib as a Novel Therapy for Renal Cell Carcinoma.
- Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell Carcinoma.
- Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer.
- Percutaneous cryoablation of metastatic renal cell Carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation.
- Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
- Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate Cancer.
- Nephrectomy in the management of metastatic osteoSarcoma.
- Phase II trial of interferon and thalidomide in metastatic renal cell Carcinoma.
- Racial disparity in outcomes of a clinical trial population with metastatic renal cell Carcinoma.
- Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell Carcinoma: a Southwest Oncology Group study.
- Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients.
- Surgical excision of duodenal/pancreatic metastatic renal cell Carcinoma.
- Development of cabozantinib for the treatment of prostate Cancer.
- A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell Carcinoma: a Cytokine Working Group (CWG) study.
- Immunotherapy and immune evasion in prostate Cancer.
- Blastic mantle cell Lymphoma associated with Burkitt-type translocation and hypodiploidy.
- A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies.
- Racial disparity in incidence patterns and outcome of kidney Cancer.
- A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell Cancer.
- Survival analysis of distant prostate Cancer by decade (1973-1997) in the Detroit Metropolitan Surveillance, Epidemiology and End Results (SEER) Program registry: has ...
- Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic Cancer.
- Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate Cancer.
- An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate Cancer.
- Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha.
- Unusual hematologic malignancies. Case 2. Mediastinal germ cell tumor, malignant histiocytosis, and Acute leukemia.
- Outcome of relapsed non-Hodgkin's Lymphoma patients after allogeneic and autologous transplantation.
- The evolving role of systemic therapy in high risk prostate Cancer: strategies for cure in the 21st century.
- Novel gemcitabine-containing triplets in the management of urothelial Cancer.
- Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell Carcinoma.
- Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative Analysis in primary and metastatic tumors.
- Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial Cancer.
- Adjuvant chemo-/hormonal therapy trials for locally advanced prostate Cancer.
- Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenoCarcinoma.
- Taxanes: an overview of the pharmacokinetics and pharmacodynamics.
- A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic Cancer.
- A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial Cancer.
- Matrix metalloproteinase activity and osteoclasts in experimental prostate Cancer bone metastasis tissue.
- Phase II trial of fenretinide in advanced renal Carcinoma.
- Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with Cancer.
- Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate Carcinoma.
- Racial disparity in clinical course and outcome of metastatic androgen-independent prostate Cancer.
- Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic Cancer.
- PSA relapse prostate Cancer: the importance of tailored therapy.
- Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell Carcinoma.
- Update in systemic therapy of prostate Cancer: improvement in quality and duration of life.
- Neoadjuvant docetaxel and capecitabine in patients with high risk prostate Cancer.
- Lycopene and soy isoflavones in the treatment of prostate Cancer.
- Phase II trial of pegylated interferon and thalidomide in Malignant metastatic melanoma.
- Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell Cancer.
- Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial Carcinoma: results of a multicenter ...
- Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal Cancer.
- Systemic therapy of advanced urothelial Cancer.
- A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate Cancer.
- Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the Bladder.
- Longitudinal analysis of a model to predict quality of life in prostate Cancer patients and their spouses.
- A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction Cancers.
- Satraplatin: leading the new generation of Oral platinum agents.
- Safety and efficacy of sorafenib therapy in patients with metastatic kidney Cancer with impaired renal function.
- Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1...
- Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer.
- Renal Cancer: is targeted therapy really empiric?
- Safety and efficacy of molecularly targeted agents in patients with metastatic kidney Cancer with renal dysfunction.
- Progression-free survival as a predictor of overall survival in metastatic renal cell Carcinoma treated with contemporary targeted therapy.
- Management of adverse events associated with the use of everolimus in patients with advanced renal cell Carcinoma.
- Soy isoflavones in conjunction with radiation therapy in patients with prostate Cancer.
- A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate Cancer.
- Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell Carcinoma.
- Cediranib in combination with various antiCancer regimens: results of a phase I multi-cohort study.
- Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate Cancer: a Southwest Oncology Group trial S0111.
- Multifaceted and personalized therapy of advanced prostate Cancer.
Schools
Bj Medical College Pune Maharashtra University Of Health Sciences
Wayne State University
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Wayne State University School of Medicine -
B.J. Medical College - University of Pune
Hospital
-
DMC - Detroit Receiving Hospital -
DMC Harper University Hospital
Drug Facts
| NPI NUMBER | 1659318640 | |
| NPPES Provider LastName | VAISHAMPAYAN | |
| NPPES Provider FirstName | ULKA | |
| NPPES Provider ZIPCode | 482012013 | |
| NPPES Provider State | MI | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1218.0 | |
| Distinct Opioid Count | 8.0 | |
| Opioid Claim Count | 345.0 | |
| Percent Opioid Claims | 28.33 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1659318640 |
| Last Name Of The Provider | VAISHAMPAYAN |
| First Name Of The Provider | ULKA |
| View All |
Similar Doctors
|
Dr. Joseph C. Won, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Preetha Ramalingam, MD |
|
|
Dr. Mohamad A. Younes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John F. Ensley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ahmed O. Kaseb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nazik Hammad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zeina A. Nahleh, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Randa Loutfi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hirva M. Mamdani, MD |
|
|
Dr. Bhaumik Patel, MD
This Doctor is OpenDoctor Recommended.
|